NASDAQ:TSPT

As of October 30, 2014, Transcept Pharmaceuticals, Inc. was acquired by Paratek Pharmaceuticals, Inc., in a reverse merger transaction. Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. The company principal product include Intermezzo sublingual tablet C-IV, a sublingual formulation of zolpidem for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Its lead product candidate is TO-2070, a rapidly absorbed treatment for acute migraine. The company has a collaboration agreement with Purdue Pharmaceutical Products, L.P. for the commercialization of Intermezzo in the United States, as well as granted the right to negotiate for the commercialization of Intermezzo in Mexico and Canada. Transcept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Point Richmond, California.